Le Lézard
Classified in: Health, Science and technology, Business
Subjects: FNC, PER

Ardian strengthens its commitment to Dedalus, driving the next phase of growth with a new investment and the appointment of a new Group CEO


Ardian agreed to increase its stake in Dedalus to 92%, with founder Giorgio Moretti retaining a 6% stake in the Company and remaining board member; Alberto Calcagno appointed Group CEO and Andrea Fiumicelli made Chairman

MILAN, Oct. 19, 2023 /PRNewswire-PRWeb/ -- A consortium led by Ardian, a world leading private investment house, has agreed to acquire an additional 19% stake in Dedalus, a leading European player in the healthcare software industry, from founder Giorgio Moretti. Subject to customary authorizations by the competent authorities, upon completion of the transaction, the consortium led by Ardian will indirectly hold a 92% stake in the Company, with Moretti retaining a 6% stake and a seat in the board.

Ardian is fully committed to supporting Dedalus throughout its next period of growth, in which it aims to serve its clients and deliver its mission of improving healthcare for over 500 million patients globally. - Marco Bellini

The agreement aims to support Dedalus through a new phase of expansion.

As part of this growth plan, Alberto Calcagno, former CEO of Italian ICT company Fastweb, which has seen significant constant growth over the past 10 years, has been appointed as new CEO, effective from October 18.

Andrea Fiumicelli, who has managed Dedalus over the last few years and contributed significantly to the company's further development through several strategic M&A deals, has been appointed Chairman.

"Ardian is fully committed to supporting Dedalus throughout its next period of growth, in which it aims to serve its clients and deliver its mission of improving healthcare for over 500 million patients globally. Ardian and I want to thank Giorgio Moretti for his vision and execution since our initial investment".

"After a long journey that began in Florence 40 years ago, the time has come for Dedalus to expand. This agreement will help the company to further invest in innovation, in line with our mission. Alberto Calcagno will bring strong skills and new energy to the Group's operations and future strategic development. I will remain a shareholder in Dedalus, together with my longtime partner Three Hills, fully supporting the new CEO and the company's project".

"I am very happy to join Dedalus to drive its ambitious growth plans. Today, the healthcare software industry is privileged to have the responsibility of leading on critical digital transformation to improve the well-being of millions of patients. Dedalus' mission is to accelerate and deliver this change as soon as possible".

"In the last four years we have successfully re-designed our software portfolio and established sales and delivery operations in 25 countries. This new governance structure strengthens our commitment to our mission and future clients. We aim to deliver faster innovation and high-quality services, be the best employer in the sector and serve our shareholders' ambitions".

Ardian has invested in Dedalus in several stages since 2016, supporting a strong M&A strategy which has seen the Company become a pan-European leader in its sector.

ABOUT ARDIAN
Ardian is a world-leading private investment house, managing or advising $156bn of assets on behalf of more than 1,470 clients globally. Our broad expertise, spanning Private Equity, Real Assets and Credit, enables us to offer a wide range of investment opportunities and respond flexibly to our clients' differing needs. Through Ardian Customized Solutions we create bespoke portfolios that allow institutional clients to specify the precise mix of assets they require and to gain access to funds managed by leading third-party sponsors. Private Wealth Solutions offers dedicated services and access solutions for private banks, family offices and private institutional investors worldwide. Ardian's main shareholding group is its employees and we place great emphasis on developing its people and fostering a collaborative culture based on collective intelligence. Our 1,050+ employees, spread across 16 offices in Europe, the Americas, Asia and Middle East are strongly committed to the principles of Responsible Investment and are determined to make finance a force for good in society. Our goal is to deliver excellent investment performance combined with high ethical standards and social responsibility.
At Ardian we invest all of ourselves in building companies that last.

ABOUT DEDALUS
Founded in 1982 in Florence by Giorgio Moretti, Dedalus Group is the leading healthcare and diagnostic software provider in Europe, supporting globally the digital transformation of 6700 Healthcare Organisations and 5700 Labs and Diagnostic centres worldwide, processing its solutions for more than 540 millions of population worldwide. Dedalus offer supports the whole continuum of care, offering open standards-based solutions serving each actor of the Healthcare Ecosystem to provide better care in a healthier planet. Life Flows through our software.
dedalus.com

Media Contact

Kathy Silverstein, On The Marc Media, (301) 545-0108, [email protected], https://onthemarcmedia.com/

SOURCE Dedalus


These press releases may also interest you

at 02:00
QuTEM AB (formerly Vironova BioAnalytics AB), a leading provider of transmission electron microscopy (TEM) services, proudly announces the receipt of GMP (Good Manufacturing Practice) Certificates and Manufacturing Permits for Independent Quality...

at 01:54
FIRST QUARTER (JANUARY - MARCH 2024) Oder intake SEK 238.5 M (206.6)Net sales SEK 257.2 M (230.2)Operating profit SEK 45.8 M (23.7)Profit after tax SEK 36.7 M (17.6)Earnings per share before/after dilution SEK 1.07 (0.51)Cash flow SEK 87.9 M...

at 01:00
In response to valuable feedback from our customers, Luraco Technologies is thrilled to announce the launch of an upgrade to our medical massage chair lineup. We are introducing the Luraco i9 Max Plus Series, a revolution of the i9 Max Series. The i9...

at 00:01
Celltrion USA today announced it will present the two-year results from the extended LIBERTY studies (LIBERTY-CD and LIBERTY-UC) in adult patients...

16 mai 2024
Proteologix, Inc., a privately-held biotechnology company focused on bispecific antibodies for immune-mediated diseases, today announced that it has entered into a definitive agreement to be acquired by Johnson & Johnson for $850 million in cash,...

16 mai 2024
Seelos Therapeutics, Inc. ("Seelos" or the "Company"), a clinical-stage biopharmaceutical company focused on the development of therapies for central nervous system ("CNS") disorders and rare diseases, announced today that it has entered into a...



News published on and distributed by: